Inflammation is gaining widespread attention for its role in the initiation and progression of cardiovascular disease. Intensive insulin therapy with tight glucose control is reported to result in reduced morbidity and mortality in inflammation related critical illness. Experimental evidence revealed that insulin attenuates the systemic inflammatory response in rats subjected to thermal trauma or endotoxin. Clinical studies reported that insulin decreases plasma levels of high-sensitivity C-reactive protein (CRP) and serum amyloid A (SAA) in patients with acute myocardial infarction (AMI) or undergoing coronary artery bypass grafts (CABGs).